AR043510A1 - Derivados de quinolinona, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden - Google Patents
Derivados de quinolinona, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR043510A1 AR043510A1 ARP040100739A ARP040100739A AR043510A1 AR 043510 A1 AR043510 A1 AR 043510A1 AR P040100739 A ARP040100739 A AR P040100739A AR P040100739 A ARP040100739 A AR P040100739A AR 043510 A1 AR043510 A1 AR 043510A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- prepare
- preparation
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
La presente se refiere a derivados de quinolinona, procedimiento para su preparación, su uso para preparar un medicamento y composiciones farmacéuticas que los comprenden. Los mismos son utilizados para el tratamiento de psicosis, esquizofrenia, manías depresivas, Parkinson, Alzheimer, Huntington y trastornos del tracto gastrointestinal. Reivindicación 1: Un compuesto de la fórmula (1) y sales farmacéuticamente aceptables o profármacos de los mismos, en la que m es un número de 0 a 4; p es un número de 1 a 3; q es un número de 1 a 3; r es un número de 1 a 3; A es arileno o heteroarileno; E es N o C; X es O, S, o -CRaRb- en la que Ra y Rb con independencia entre si son H o alquilo; cada R1 con independencia de su aparición es halo, alquilo, haloalquilo, heteroalquilo, hidroxi, nitro, alcoxi, ciano, -S(O)sRc, -NRcRd, -C(=O)-NRcRd, -SO2-NRcRd-N(Rc-C(=O)-Rd o -C(=O)-Rc, en la que s es un número de 0 a 2 y Rc y Rd con independencia entre si son H o alquilo; Y es -(CR2R3)n- en la que n es 1 0 2 y R2 y R3 con independencia entre si son H o alquilo, o X e Y, juntos, forman un grupo alquenileno y R4, R5, R6, R7, R8, R9 y R10 con independencia entre sí son H o alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45357403P | 2003-03-11 | 2003-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043510A1 true AR043510A1 (es) | 2005-08-03 |
Family
ID=32990787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100739A AR043510A1 (es) | 2003-03-11 | 2004-03-09 | Derivados de quinolinona, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6943169B2 (es) |
| EP (1) | EP1603880B1 (es) |
| JP (1) | JP4404893B2 (es) |
| KR (1) | KR100691090B1 (es) |
| CN (1) | CN100455570C (es) |
| AR (1) | AR043510A1 (es) |
| AT (1) | ATE394377T1 (es) |
| AU (1) | AU2004220388B9 (es) |
| BR (1) | BRPI0408204A (es) |
| CA (1) | CA2518403A1 (es) |
| CL (1) | CL2004000450A1 (es) |
| CO (1) | CO5601030A2 (es) |
| DE (1) | DE602004013560D1 (es) |
| ES (1) | ES2305742T3 (es) |
| HR (1) | HRP20050775A2 (es) |
| MX (1) | MXPA05009523A (es) |
| MY (1) | MY135470A (es) |
| NO (1) | NO20054135L (es) |
| NZ (1) | NZ541642A (es) |
| RU (1) | RU2333204C2 (es) |
| TW (1) | TWI289141B (es) |
| WO (1) | WO2004080969A1 (es) |
| ZA (1) | ZA200506831B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101020399B1 (ko) | 2002-03-27 | 2011-03-08 | 글락소 그룹 리미티드 | 퀴놀린 유도체 및 5-ｈｔ6 리간드로서의 그의 용도 |
| CA2533369C (en) | 2003-07-22 | 2009-07-14 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| US7592457B2 (en) * | 2004-10-20 | 2009-09-22 | Korea Research Institute Of Chemical Technology | 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same |
| NZ582124A (en) * | 2007-05-21 | 2012-07-27 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
| WO2009009135A1 (en) * | 2007-07-11 | 2009-01-15 | Dow Corning Corporation | Compositions for delivering a drug |
| EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| EP2163541A1 (en) * | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| AU2012324015A1 (en) | 2011-12-01 | 2013-06-20 | Purdue Pharma L.P. | Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof |
| MX2017016413A (es) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CN114085179B (zh) * | 2021-11-29 | 2024-05-03 | 福建科宏生物工程股份有限公司 | 一种n-乙酰基-5-甲氧基色胺的制备方法 |
| WO2023192430A1 (en) * | 2022-03-30 | 2023-10-05 | University Of Florida Research Foundation, Incorported | Compounds for treating psychostimulant misuse |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3733321A (en) * | 1971-07-06 | 1973-05-15 | Squibb & Sons Inc | 1,4-benzothiazin-3-ones |
| US4078062A (en) * | 1976-10-28 | 1978-03-07 | E. R. Squibb & Sons, Inc. | Substituted 2H-1,4-benzothiazin-3(4H)-ones |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| HUP0003073A3 (en) * | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
| HUP0101699A3 (en) | 1998-03-31 | 2002-05-28 | Warner Lambert Co | Benzoxazinones/benzothiazinones as serine protease inhibitors and pharmaceutical compositions containing the same |
| KR20010042298A (ko) * | 1998-03-31 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논 |
| US6855726B1 (en) | 1998-03-31 | 2005-02-15 | Warner-Lambert Company Llc | Quinolones as serine protease inhibitors |
| GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| EP1255743A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa |
| WO2001057019A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| ATE337780T1 (de) * | 2000-11-24 | 2006-09-15 | Smithkline Beecham Plc | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns |
| CN1254469C (zh) * | 2001-08-10 | 2006-05-03 | 弗·哈夫曼-拉罗切有限公司 | 具有5－ht6受体亲和性的芳基磺酰基衍生物 |
| US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
-
2004
- 2004-03-05 TW TW093105911A patent/TWI289141B/zh not_active IP Right Cessation
- 2004-03-08 DE DE602004013560T patent/DE602004013560D1/de not_active Expired - Lifetime
- 2004-03-08 JP JP2006500055A patent/JP4404893B2/ja not_active Expired - Fee Related
- 2004-03-08 ES ES04718298T patent/ES2305742T3/es not_active Expired - Lifetime
- 2004-03-08 KR KR1020057016880A patent/KR100691090B1/ko not_active IP Right Cessation
- 2004-03-08 BR BRPI0408204-4A patent/BRPI0408204A/pt not_active IP Right Cessation
- 2004-03-08 MX MXPA05009523A patent/MXPA05009523A/es active IP Right Grant
- 2004-03-08 CN CNB2004800065778A patent/CN100455570C/zh not_active Expired - Fee Related
- 2004-03-08 RU RU2005131172/04A patent/RU2333204C2/ru not_active IP Right Cessation
- 2004-03-08 AT AT04718298T patent/ATE394377T1/de not_active IP Right Cessation
- 2004-03-08 EP EP04718298A patent/EP1603880B1/en not_active Expired - Lifetime
- 2004-03-08 WO PCT/EP2004/002340 patent/WO2004080969A1/en active IP Right Grant
- 2004-03-08 AU AU2004220388A patent/AU2004220388B9/en not_active Ceased
- 2004-03-08 CA CA002518403A patent/CA2518403A1/en not_active Abandoned
- 2004-03-08 CL CL200400450A patent/CL2004000450A1/es unknown
- 2004-03-08 NZ NZ541642A patent/NZ541642A/en unknown
- 2004-03-09 AR ARP040100739A patent/AR043510A1/es not_active Application Discontinuation
- 2004-03-10 MY MYPI20040829A patent/MY135470A/en unknown
- 2004-03-10 US US10/797,545 patent/US6943169B2/en not_active Expired - Fee Related
-
2005
- 2005-07-27 US US11/191,092 patent/US7476675B2/en not_active Expired - Fee Related
- 2005-08-25 CO CO05085018A patent/CO5601030A2/es not_active Application Discontinuation
- 2005-08-25 ZA ZA200506831A patent/ZA200506831B/en unknown
- 2005-09-05 HR HR20050775A patent/HRP20050775A2/xx not_active Application Discontinuation
- 2005-09-06 NO NO20054135A patent/NO20054135L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043510A1 (es) | Derivados de quinolinona, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
| MX2017011951A (es) | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. | |
| HRP20211072T1 (hr) | Sinteza indazola | |
| UY28339A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| AR036057A1 (es) | Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| WO2008019967A3 (en) | Phenyl, pyridine and quinoline derivatives | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
| AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| MX369956B (es) | Metodos para preparar compuestos de benzoquinolina. | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| AR040489A1 (es) | Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen | |
| AR052413A1 (es) | Nuevos derivados de piridotienopiriidina | |
| BRPI0416564A (pt) | novas prostamidas para o tratamento de glaucoma e doenças relacionadas | |
| AR042155A1 (es) | Aminoalcoxiindoles, composicion farmaceutica que los comprenden y usos | |
| AR040960A1 (es) | Derivados de tiazol | |
| AR076516A1 (es) | Derivados de oxa-azaespiro[3.3]heptan-6-ilo, metodo e intermediarios para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor mch1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FA | Abandonment or withdrawal | ||
| FA | Abandonment or withdrawal |